{"id":23105,"date":"2026-05-29T11:54:47","date_gmt":"2026-05-29T11:54:47","guid":{"rendered":"https:\/\/engineerbabu.com\/blog\/?p=23105"},"modified":"2026-05-29T12:00:38","modified_gmt":"2026-05-29T12:00:38","slug":"glp-1-digital-health-platform","status":"publish","type":"post","link":"https:\/\/engineerbabu.com\/blog\/glp-1-digital-health-platform\/","title":{"rendered":"How GLP-1 Digital Health Platforms Work in the USA And What It Takes to Build One in 2026"},"content":{"rendered":"<p><a href=\"https:\/\/www.niddk.nih.gov\/health-information\/health-statistics\/overweight-obesity\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">42.5% of American<\/span><\/a><span style=\"font-weight: 400;\"> adults currently have obesity. By 2035, that number is projected to reach 46.9%.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Semaglutide produces ~15% mean weight loss in 68 weeks. Tirzepatide produces ~20%. These are numbers the pharmaceutical industry hadn&#8217;t seen in obesity treatment in decades.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The collision of those two realities created one of the fastest-growing digital health categories of the last five years: GLP-1 telehealth platforms. Hims &amp; Hers, Ro, LifeMD, Noom, Calibrate, Found, WeightWatchers Clinic, all built technology infrastructure to connect patients to GLP-1 prescriptions at scale.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The total addressable market is 107 million Americans with obesity, most of whom have never received pharmacological treatment.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The regulatory environment in 2026, however, has shifted significantly from the compounding era that powered most of these platforms&#8217; growth. Understanding what a GLP-1 digital health platform actually is technically, legally, and clinically, is essential before building one.<\/span><\/p>\n<h2><b>What Is a GLP-1 Digital Health Platform?<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">A GLP-1 digital health platform is a technology infrastructure that connects patients seeking prescription weight management medications, primarily semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) with licensed healthcare providers for clinical evaluation, prescription, and ongoing care management.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The platform itself does not practice medicine; it enables the three-entity structure that characterizes compliant telehealth: technology platform, independent licensed clinicians, and licensed pharmacy partners.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In 2026, successful platforms are moving beyond prescription access to differentiate on outcomes, adherence support, and long-term chronic disease management infrastructure.<\/span><\/p>\n<h2><b>The Three-Entity Architecture Every GLP-1 Platform Uses<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Understanding this structure is foundational, both for compliance and for product design. Every compliant GLP-1 telehealth platform in the USA operates this way:<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>Entity 1: The Technology Platform<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><b>The platform itself: <\/b><span style=\"font-weight: 400;\">patient onboarding, intake forms, clinical communication tools, prescription routing, medication fulfillment coordination, billing, patient engagement features. The technology company is not a healthcare provider. It does not employ clinicians (in most structures). It builds and operates the infrastructure through which care is delivered.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>Entity 2: Independent Licensed Clinicians \/ Medical Groups<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The prescribing physicians, nurse practitioners, and physician assistants are organized as independent medical practices or affiliated medical groups that use the platform&#8217;s technology. This separation is legally significant, it preserves the independence of clinical judgment from business incentives.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The clinician reviews the patient intake, evaluates eligibility, and makes independent prescribing decisions. A patient completing an intake form is not guaranteed a prescription.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>Entity 3L: Licensed Pharmacy Partners<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Fulfillment of GLP-1 prescriptions requires a licensed pharmacy. For branded FDA-approved medications (Wegovy, Zepbound), platforms partner with specialty pharmacies or manufacturers directly. For compounded semaglutide or tirzepatide (during shortage periods), platforms partner with licensed compounding pharmacies.<\/span><\/p>\n<p><b>The regulatory line:<\/b><span style=\"font-weight: 400;\"> The technology platform cannot cross into clinical decision-making. Intake questionnaires inform the clinician but do not determine the prescription. Algorithmic eligibility screening can facilitate the workflow but cannot substitute for licensed clinician review. This line has regulatory and legal enforcement behind it.<\/span><\/p>\n<h2><b>The 2026 Regulatory Inflection: Compounding Is Being Shut Down<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Every GLP-1 platform that scaled on compounded semaglutide is now navigating a forced transition.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The FDA declared the semaglutide shortage resolved on February 21, 2025. When a shortage is resolved, the legal basis for compounding pharmacies to produce copies of brand-name drugs evaporates.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In February 2026, FDA Commissioner Marty Makary announced the agency&#8217;s intent to crack down on non-FDA-approved GLP-1 compounding. Novo Nordisk filed a legal challenge against Hims &amp; Hers, characterizing mass compounding of semaglutide as illegal given the shortage resolution.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This regulatory shift has three practical effects on GLP-1 platforms:<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>Compounded medication revenue models are under existential pressure<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Platforms that built their unit economics around compounded semaglutide at $199\u2013$349\/month are losing their cost advantage as FDA enforcement increases. FDA-approved Wegovy costs $1,000\u2013$1,350\/month at full price without insurance.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>TrumpRx changes the access math starting July 2026.<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The Trump administration announced negotiated pricing agreements with Novo Nordisk and Eli Lilly, Ozempic, Wegovy, Mounjaro, and Zepbound will be priced at $245\/month through the TrumpRx platform. Medicare beneficiaries will pay just $50\/month in copay starting July 2026. This dramatically increases the accessible patient population for branded medications and makes the compounding price advantage less significant.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>The differentiation question<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">When semaglutide is $245\/month and prescribable through any platform, the access arbitrage that powered the first generation of GLP-1 platforms disappears. The platforms that survive are the ones that built longitudinal care infrastructure, adherence support, behavioral change programming, comorbidity management, outcome tracking rather than just prescription access.<\/span><\/p>\n<h2><b>What a GLP-1 Platform Actually Needs to Build<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">This is the technical specification that most product discussions skip. Here is the complete module breakdown:<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>Module 1: Patient Intake and Eligibility Assessment<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The clinical onboarding flow: demographic information, weight\/BMI capture, medical history (current medications, contraindications, prior weight loss attempts), comorbidity screening (T2DM, hypertension, cardiovascular disease, GLP-1s have additional indications beyond obesity for these conditions), and written informed consent.<\/span><\/p>\n<p><b>Technical requirements:<\/b><span style=\"font-weight: 400;\"> HIPAA-compliant form infrastructure (<\/span><a href=\"https:\/\/engineerbabu.com\/blog\/what-is-hipaa-baa-healthcare-apps-usa\/\"><span style=\"font-weight: 400;\">HIPAA BAA<\/span><\/a><span style=\"font-weight: 400;\"> required with form tool), clinical questionnaire logic with branching based on responses, PHI stored in encrypted database, consent management with audit trail. This is not a standard web form, it is a regulated clinical intake that feeds a licensed clinician&#8217;s review.<\/span><\/p>\n<p><b>The contraindication screening layer:<\/b><span style=\"font-weight: 400;\"> GLP-1 receptor agonists are contraindicated for patients with personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and active pancreatitis. The intake must screen for these. Failure to screen creates clinical and legal liability.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>Module 2: Clinician Review and Prescribing Workflow<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">After intake submission, the case routes to a licensed clinician&#8217;s queue. The clinician reviews the intake, evaluates eligibility against clinical guidelines (typically BMI \u226530, or \u226527 with weight-related comorbidities), may conduct a synchronous or asynchronous video\/chat consultation, makes the prescribing decision, and transmits the prescription electronically.<\/span><\/p>\n<p><b>Technical requirements:<\/b><span style=\"font-weight: 400;\"> Provider dashboard with patient queue management, asynchronous messaging with <\/span><a href=\"https:\/\/engineerbabu.com\/blog\/how-to-build-a-hipaa-compliant-app\/\"><span style=\"font-weight: 400;\">HIPAA-compliant<\/span><\/a><span style=\"font-weight: 400;\"> secure messaging, telemedicine video (Twilio Video or Daily.co with BAA for synchronous consults), e-prescribing integration (Surescripts for controlled substance-compliant prescription transmission), and clinical notes documentation.<\/span><\/p>\n<p><b>The clinical decision engine question:<\/b><span style=\"font-weight: 400;\"> Some platforms use algorithmic pre-screening to route patients to providers more efficiently. This is appropriate, the algorithm can surface contraindications, flag high-risk patients for synchronous consultation, and pre-populate clinical notes. The algorithm cannot substitute for the clinician&#8217;s final determination. This distinction is what separates compliant platforms from those drawing regulatory scrutiny.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>Module 3: Pharmacy Integration and Fulfillment<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The prescription routes to a licensed pharmacy partner. For branded medications, this means specialty pharmacy networks (NovoCare, LillyDirect, CenterWell Specialty Pharmacy) or retail pharmacies via Surescripts. For compounded medications during shortage periods, compounding pharmacy partners.<\/span><\/p>\n<p><b>Technical requirements:<\/b><span style=\"font-weight: 400;\"> E-prescribing <\/span><a href=\"https:\/\/engineerbabu.com\/blog\/healthcare-api-integration-use-cases\/\"><span style=\"font-weight: 400;\">API integration<\/span><\/a><span style=\"font-weight: 400;\"> (Surescripts or pharmacy-specific APIs), prescription status tracking (transmitted, received, dispensed, shipped), medication shipment tracking integration, refill management with clinical oversight for dose titration, and prior authorization support for insurance-covered prescriptions.<\/span><\/p>\n<p><b>The prior authorization reality for GLP-1s:<\/b><span style=\"font-weight: 400;\"> Most commercial insurance plans require prior authorization for GLP-1 medications. The AI prior authorization framework from Blog 5 applies directly here: platforms that automate PA submission, pulling clinical documentation from the intake, mapping to payer criteria, submitting via FHIR-based PAS or X12 278, dramatically improve patient access rates and reduce dropout at the authorization stage.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>Module 4: Ongoing Care Management and Adherence<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">This is where first-generation platforms left the most value on the table and where second-generation platforms are differentiating.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">GLP-1 medications require dose titration over weeks: semaglutide typically escalates from 0.25mg to 2.4mg over 16\u201320 weeks. Side effect management (nausea affects 15\u201320% of patients in the first month) requires clinical touchpoints. Long-term adherence is the core challenge, patients who stop GLP-1 medications typically regain significant weight.<\/span><\/p>\n<p><b>Features that drive outcomes and retention:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Dose titration tracking with clinical alerts when escalation is due<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Side effect reporting with automated triage (mild nausea = educational content; severe vomiting = clinician notification)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Weight and biometric logging (integrated with scale devices, Apple Health, Google Fit)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Dietary and behavioral coaching (synchronous with registered dietitians or asynchronous with AI-driven coaching)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Lab monitoring reminders (HbA1c tracking for diabetic patients, lipid panels)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Refill coordination with proactive outreach before medication runs out<\/span><\/li>\n<\/ul>\n<p><b>The AI layer in 2026:<\/b><span style=\"font-weight: 400;\"> AI-driven coaching that analyzes patient adherence patterns, predicts dropout risk, and triggers personalized outreach before a patient stops engaging is the technology that moves GLP-1 platforms from prescription access tools to chronic disease management platforms.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The platforms with the best long-term outcomes and the best unit economics from patient LTV are the ones investing here.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>Module 5: Billing, Insurance, and Revenue Management<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><b>Self-pay:<\/b><span style=\"font-weight: 400;\"> Most GLP-1 telehealth platforms today operate primarily on self-pay economics, subscription fees covering consultation, monitoring, and sometimes medication. Pricing typically ranges from $99\u2013$299\/month for platform fees, plus separate medication costs.<\/span><\/p>\n<p><b>Insurance billing:<\/b><span style=\"font-weight: 400;\"> Wegovy is covered under many commercial plans for patients with BMI \u226530 and at least one weight-related comorbidity. TrumpRx Medicare coverage starts July 2026 at $245\/month ($50\/month copay for beneficiaries). Building insurance billing capability, claims submission, ERA processing, denial management, significantly expands the addressable market but adds substantial compliance infrastructure.<\/span><\/p>\n<p><b>Technical requirements for insurance billing:<\/b><span style=\"font-weight: 400;\"> EDI 837 claim generation, ERA\/EOB parsing, benefit eligibility verification (Availity or Change Healthcare), prior authorization workflow, and denial appeals management.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>Module 6: Regulatory and Compliance Infrastructure<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><b>HIPAA compliance:<\/b><span style=\"font-weight: 400;\"> Full infrastructure including AES-256 encryption, TLS 1.3 in transit, RBAC, 6-year audit logging, BAAs with all vendors, annual penetration testing.<\/span><\/p>\n<p><b>DEA and state pharmacy regulations:<\/b><span style=\"font-weight: 400;\"> E-prescribing of GLP-1 medications is subject to state-by-state telehealth prescribing laws. Some states require an in-person examination before prescribing; most have maintained pandemic-era telehealth flexibilities. The platform must track clinician licensing by state and route patients to appropriately licensed providers.<\/span><\/p>\n<p><b>Ryan Haight Act compliance:<\/b><span style=\"font-weight: 400;\"> For any controlled substances (not GLP-1s specifically, but if the platform expands to other medications), the DEA&#8217;s Ryan Haight Act requires an in-person evaluation before prescribing. GLP-1 receptor agonists are not controlled substances, but this is an important architectural constraint as platforms expand their medication portfolios.<\/span><\/p>\n<h2><b>The Technical Stack<\/b><\/h2>\n<table>\n<tbody>\n<tr>\n<td><b>Layer<\/b><\/td>\n<td><b>Component<\/b><\/td>\n<td><b>Notes<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Patient app<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Flutter (iOS + Android)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Biometric logging, coaching, messaging<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Web platform<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Next.js<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Patient portal, provider dashboard<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Backend<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Python FastAPI or Node.js NestJS<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Clinical workflow orchestration<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Database<\/span><\/td>\n<td><span style=\"font-weight: 400;\">PostgreSQL (AWS RDS, AES-256)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">PHI in separate encrypted schema<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">E-prescribing<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Surescripts API<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Prescription transmission and status<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Video consults<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Twilio Video (HIPAA BAA)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Synchronous clinical consultations<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Messaging<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Twilio (HIPAA BAA)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Async patient-provider communication<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">AI coaching<\/span><\/td>\n<td><span style=\"font-weight: 400;\">GPT-4o via Azure OpenAI (HIPAA BAA)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Personalized adherence coaching<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Lab integration<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Labcorp\/Quest FHIR APIs<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Lab result ingestion<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Prior auth<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Da Vinci PAS \/ X12 278<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Insurance PA submission<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Wearables<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Apple Health \/ Google Health Connect<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Weight, activity, glucose data<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Infrastructure<\/span><\/td>\n<td><span style=\"font-weight: 400;\">AWS HIPAA-eligible<\/span><\/td>\n<td><span style=\"font-weight: 400;\">All HIPAA-eligible services<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><b>The Build Economics<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">A GLP-1 digital health platform has two distinct build scopes:<\/span><\/p>\n<p><b>Prescription access platform (MVP):<\/b><span style=\"font-weight: 400;\"> Intake \u2192 clinician review \u2192 e-prescribe \u2192 pharmacy fulfillment \u2192 basic refill management. Cost range: <\/span><b>$80,000\u2013$150,000<\/b><span style=\"font-weight: 400;\">. Timeline: 14\u201320 weeks. This is the minimum viable platform that can legally operate.<\/span><\/p>\n<p><b>Full chronic disease management platform:<\/b><span style=\"font-weight: 400;\"> All <\/span><a href=\"https:\/\/engineerbabu.com\/services\/mvp-development\"><span style=\"font-weight: 400;\">MVP modules<\/span><\/a><span style=\"font-weight: 400;\"> plus insurance billing, prior authorization, AI adherence coaching, RPM device integration, behavioral health integration, lab monitoring, population health analytics. Cost range: <\/span><b>$300,000\u2013$700,000<\/b><span style=\"font-weight: 400;\">. Timeline: 18\u201330 months.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The unit economics that justify the larger build: a GLP-1 patient with good adherence over 24 months generates $2,400\u2013$7,200 in platform revenue. The platforms competing purely on prescription access are racing to the bottom.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The platforms competing on outcomes, demonstrable weight loss, comorbidity improvement, cardiovascular risk reduction are building sustainable businesses and attracting payer contracts.<\/span><\/p>\n<p><b>Author:<\/b><span style=\"font-weight: 400;\"> Mayank Pratap | Co-Founder, EngineerBabu | Google AI Accelerator 2024 \u00b7 CMMI Level 5<\/span><\/p>\n<h2><b>FAQ<\/b><\/h2>\n<ul>\n<li aria-level=\"1\">\n<h3><b>What is a GLP-1 digital health platform?<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">A technology platform connecting patients with licensed clinicians for GLP-1 prescription evaluation and ongoing care management, using a three-entity structure: technology platform, independent clinical providers, and licensed pharmacy partners. The platform does not practice medicine, it enables the infrastructure through which care is delivered.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>Is compounded semaglutide still legal in 2026?<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The FDA resolved the semaglutide shortage on February 21, 2025, eliminating the shortage-based justification for compounding. FDA enforcement against non-FDA-approved compounded GLP-1 medications increased significantly in early 2026. Platforms should consult healthcare regulatory counsel for current compliance status, the regulatory environment is actively evolving.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>How much does it cost to build a GLP-1 telehealth platform?<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">A compliant prescription access MVP costs $80,000\u2013$150,000. A full chronic disease management platform with insurance billing, AI coaching, and RPM integration costs $300,000\u2013$700,000. Annual maintenance runs 15\u201320% of build cost.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>What medications do GLP-1 platforms prescribe?<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Primarily semaglutide (Wegovy for obesity, Ozempic for T2DM) and tirzepatide (Zepbound for obesity, Mounjaro for T2DM). Some platforms also offer other weight management medications (phentermine, bupropion\/naltrexone) and are expanding to adjacent GLP-1 indications including cardiovascular risk reduction.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>What is TrumpRx and how does it affect GLP-1 platforms?<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">TrumpRx is a federal program negotiating manufacturer pricing agreements for GLP-1 medications, bringing Ozempic, Wegovy, Mounjaro, and Zepbound to $245\/month, with a $50\/month Medicare copay starting July 2026. This expands the accessible patient population for branded medications and reduces the price advantage of compounded alternatives.<\/span><\/p>\n<ul>\n<li aria-level=\"1\">\n<h3><b>Do GLP-1 platforms need prior authorization integration?<\/b><\/h3>\n<\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">For commercially insured patients accessing FDA-approved GLP-1 medications, yes. Prior authorization is required by most commercial plans. Platforms with automated PA workflows, AI-assisted clinical documentation extraction, FHIR-based PAS submission, achieve higher first-pass approval rates and better patient access outcomes.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>42.5% of American adults currently have obesity. By 2035, that number is projected to reach 46.9%. Semaglutide produces ~15% mean weight loss in 68 weeks. Tirzepatide produces ~20%. These are numbers the pharmaceutical industry hadn&#8217;t seen in obesity treatment in decades. The collision of those two realities created one of the fastest-growing digital health categories [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":23106,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1246],"tags":[],"class_list":["post-23105","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthtech"],"_links":{"self":[{"href":"https:\/\/engineerbabu.com\/blog\/wp-json\/wp\/v2\/posts\/23105","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/engineerbabu.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/engineerbabu.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/engineerbabu.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/engineerbabu.com\/blog\/wp-json\/wp\/v2\/comments?post=23105"}],"version-history":[{"count":1,"href":"https:\/\/engineerbabu.com\/blog\/wp-json\/wp\/v2\/posts\/23105\/revisions"}],"predecessor-version":[{"id":23107,"href":"https:\/\/engineerbabu.com\/blog\/wp-json\/wp\/v2\/posts\/23105\/revisions\/23107"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/engineerbabu.com\/blog\/wp-json\/wp\/v2\/media\/23106"}],"wp:attachment":[{"href":"https:\/\/engineerbabu.com\/blog\/wp-json\/wp\/v2\/media?parent=23105"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/engineerbabu.com\/blog\/wp-json\/wp\/v2\/categories?post=23105"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/engineerbabu.com\/blog\/wp-json\/wp\/v2\/tags?post=23105"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}